“…SIMPLE SUMMARY: Patients with HER2-positive metastatic breast cancer develop brain metastases in up to 30% of cases. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, we reviewed recent clinical trials involving combination therapies with mAbs targeting the PD-1/PD-L1 axis and Her-2/neu, which was chosen as a paradigm for a clinically highly relevant TAA. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Retained thermodynamic stability as well as retained binding to both HER2 and albumin was verified. Furthermore, HER2 binding specificity of the radiolabeled Affibody molecule was confirmed by an in vitro saturation assay showing a significantly higher cell-bound activity of SKOV-3 (high HER2 expression) compared with BxPC3 (low HER2 expression), both in the presence and absence of HSA. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The aim of this study was to retrospectively evaluate the efficacy of full management from first-line to third-line treatments in patients with human epidermal growth factor receptor 2 (Her-2)–negative advanced gastric cancer (GC). METHODS: The efficacy and survival time of a total of 126 patients who received the first-line treatment with oxaliplatin plus fluoropyrimidine (S-1 or capecitabine or fluorouracil), the second-line treatment with nab-paclitaxel, and the third-line treatment of immune checkpoint inhibitors between September 2019 and December 2021 were analyzed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Adjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Novel anti-HER2 antibody–drug conjugates showed convincing efficacy in HER2-Low breast cancer patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In the present review, we describe a unique case of HER-2-positive primary BNEN with a signet ring feature that has not been reported in English. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The development of novel anti-HER2 drugs opens new treatment options for women with breast cancers, including lower expression of HER2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high metastatic potential. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Kaplan-Meier and log-rank tests were used to evaluate the effect of HER2/GRB7 co-expression on patients’ survival. RESULTS: Our results show that patients with higher IA ancestry have higher odds of having HER2+/GRB7- breast tumors, compared to the HER2-/GRB7- subtype, and this association seems to be stronger among ER-positive tumors (ER+/HER2+/GRB7-: OR=3.04, 95% CI, 1.47-6.37, p<0.05). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DEBBRAH aims to assess T-DXd in patients with HER2-positive or HER2-low ABC and central nervous system involvement. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Accurate evaluation of human epidermal growth factor receptor 2 (HER2) status is very important for appropriate management of advanced gastric cancer (AGC) patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…To obtain this dataset, two human HER2-positive breast cancer cell lines (SKBR3 and MDA-MB-453 cell lines) were cultured in basal growth media to 80% confluence. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpressed associated with poor prognosis in breast cancer and HER2 has been defined as a therapeutic target for breast cancer treatment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…AUC5 may be the optimal carboplatin dose to reduce TCHP‐induced anaemia in patients with HER2+ breast cancer treated with TCHP.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: The conventional CT-based radiomics model had a good diagnostic performance of HER2 positivity in GC and the potential to generalize to DECT, which is beneficial to simplify clinical workflow and help clinicians initially identify potential candidates who might benefit from HER2-targeted therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Moreover, S100A9 silencing significantly altered lactate production, glucose uptake and ECAR levels in HER2+ cell lines. Co-expression of S100A9 and c-Myc was detected in HER2+ tissues. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We report a clinical case of a 33-year-old man who was diagnosed with right breast cancer, initially Her2 negative in the CNB. Therefore, the NAC was completed without anti-Her2 treatment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A year course of trastuzumab revolutionized treatment for human epidermal growth factor receptor (HER2)-positive breast cancer by increasing survival rates. …”
Enlace del recurso
Enlace del recurso